Basic Information (Switzerland) Elecon Asia SA (hereinafter referred to as “Elecon”) is a powerful intelligent three-d...
Digital Copyright Ten Major Typical Cases 1.Short Video Copyright Case: Whether a Short Video is Original Has Nothing to...
December 7, 2023 - News of a patent infringement ruling against Apple Watches a few weeks ago caused a flurry of investo...
Dec 16 - Regeneron Pharmaceuticals (REGN.O) has settled allegations that it misused a patented protein to test its COVID-19 treatment REGEN-COV, according to filings in New York federal court. U.S.
innovations to develop its blockbuster COVID-19 vaccine Spikevax. The lawsuit said Moderna uses Northwestern-developed lipid nanoparticle (LNP) technology without a license in Spikevax shots to transport
While the US on Tuesday refused to join the international effort to develop a COVID-19 vaccine, China is pooling efforts in international cooperation to secure a fair distribution of COVID-19
While the US on Tuesday refused to join the international effort to develop a COVID-19 vaccine, China is pooling efforts in international cooperation to secure a fair distribution of COVID-19
with its blockbuster COVID-19 vaccine Spikevax and RSV shot mResvia. According to the two lawsuits, Moderna's lipid nanoparticles for transporting fragile mRNA into the human body infringe several
LONDON, Sept 25 (Reuters) - Pfizer and Moderna's legal battle over their rival COVID-19 vaccines will continue after London's High Court on Wednesday gave Pfizer permission to take the case to the
Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said demonstrates the vaccine's originality and creativity, and would
Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said demonstrates the vaccine's originality and creativity, and would
Chinese authorities have granted the first invention patent to a domestically developed COVID-19 vaccine candidate, which experts said demonstrates the vaccine's originality and creativity, and would
authorised the use of the patent during the COVID-19 pandemic. BioNTech and Pfizer claimed this authorisation was valid until 5 May 2023 when the World Health Organisation declared the COVID-19 pandemic
CHINA intellectual PROPERTY LAWYERS NETWORK
+86-13910160652
ciplawyers@163.com
